Hepatitis Monthly

Published by: Kowsar

Serum NX-DCP as a New Noninvasive Model to Predict Significant Liver Fibrosis in Chronic Hepatitis C

Masaya Saito 1 , * , Yoshihiko Yano 1 , 2 , Hirotaka Hirano 1 , Kenji Momose 1 , Masaru Yoshida 1 , 3 and Takeshi Azuma 1
Authors Information
1 Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
2 Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan
3 Division of Metabolomics Research, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
Article information
  • Hepatitis Monthly: February 01, 2015, 15 (2); e22978
  • Published Online: February 6, 2015
  • Article Type: Research Article
  • Received: August 22, 2014
  • Revised: November 11, 2014
  • Accepted: January 3, 2015
  • DOI: 10.5812/hepatmon.22978

To Cite: Saito M, Yano Y, Hirano H, Momose K, Yoshida M, et al. Serum NX-DCP as a New Noninvasive Model to Predict Significant Liver Fibrosis in Chronic Hepatitis C, Hepat Mon. 2015 ; 15(2):e22978. doi: 10.5812/hepatmon.22978.

Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001; 344(7): 495-500[DOI][PubMed]
  • 2. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol. 1986; 2(2): 165-73[PubMed]
  • 3. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002; 97(10): 2614-8[DOI][PubMed]
  • 4. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003; 38(6): 1449-57[DOI][PubMed]
  • 5. Le Couteur DG, Hickey H, Harvey PJ, Gready J, McLean AJ. Hepatic artery flow and propranolol metabolism in perfused cirrhotic rat liver. J Pharmacol Exp Ther. 1999; 289(3): 1553-8[PubMed]
  • 6. Copple BL. Hypoxia stimulates hepatocyte epithelial to mesenchymal transition by hypoxia-inducible factor and transforming growth factor-beta-dependent mechanisms. Liver Int. 2010; 30(5): 669-82[DOI][PubMed]
  • 7. Nitta T, Kim JS, Mohuczy D, Behrns KE. Murine cirrhosis induces hepatocyte epithelial mesenchymal transition and alterations in survival signaling pathways. Hepatology. 2008; 48(3): 909-19[DOI][PubMed]
  • 8. Pinzani M. Epithelial-mesenchymal transition in chronic liver disease: fibrogenesis or escape from death? J Hepatol. 2011; 55(2): 459-65[DOI][PubMed]
  • 9. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008; 134(6): 1655-69[DOI][PubMed]
  • 10. Murata K, Suzuki H, Okano H, Oyamada T, Yasuda Y, Sakamoto A. Cytoskeletal changes during epithelial-to-fibroblastoid conversion as a crucial mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol. 2009; 35(5): 1005-14[PubMed]
  • 11. Tanaka T, Taniguchi T, Sannomiya K, Takenaka H, Tomonari T, Okamoto K, et al. Novel des-gamma-carboxy prothrombin in serum for the diagnosis of hepatocellular carcinoma. J Gastroenterol Hepatol. 2013; 28(8): 1348-55[DOI][PubMed]
  • 12. Toyoda H, Kumada T, Osaki Y, Tada T, Kaneoka Y, Maeda A. Novel method to measure serum levels of des-gamma-carboxy prothrombin for hepatocellular carcinoma in patients taking warfarin: a preliminary report. Cancer Sci. 2012; 103(5): 921-5[DOI][PubMed]
  • 13. Rosner B. Fundamentals Of Biostatistics. 2012;
  • 14. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1998; 93(1): 44-8[DOI][PubMed]
  • 15. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003; 38(2): 518-26[DOI][PubMed]
  • 16. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology. 2007; 46(3): 912-21[DOI][PubMed]
  • 17. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011; 53(3): 726-36[DOI][PubMed]
  • 18. Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cardenas E, Sanchez-Avila F, Vargas-Vorackova F. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol. 2008; 7(4): 350-7[PubMed]
  • 19. Khairy M, Abdel-Rahman M, El-Raziky M, El-Akel W, Zayed N, Khatab H, et al. Non-invasive prediction of hepatic fibrosis in patients with chronic HCV based on the routine pre-treatment workup. Hepat Mon. 2012; 12(11)[DOI][PubMed]
  • 20. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006; 43(6): 1317-25[DOI][PubMed]
  • 21. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007; 46(1): 32-6[DOI][PubMed]
  • 22. Adler M, Gulbis B, Moreno C, Evrard S, Verset G, Golstein P, et al. The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases. Hepatology. 2008; 47(2): 762-3[DOI][PubMed]
  • 23. Islam S, Antonsson L, Westin J, Lagging M. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol. 2005; 40(7): 867-72[DOI][PubMed]
  • 24. Ehsan N, TawfikBadr MT, Raouf AA, Badra G. Correlation between liver biopsy findings and different serum biochemical tests in staging fibrosis in Egyptian patients with chronic hepatitis C virus infection. Arab J Gastroenterol . 2008; 9: 7-12
  • 25. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology. 2005; 42(2): 282-92[DOI][PubMed]
  • 26. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002; 36(4 Pt 1): 986-92[DOI][PubMed]
  • 27. Hui AY, Chan HL, Wong VW, Liew CT, Chim AM, Chan FK, et al. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol. 2005; 100(3): 616-23[DOI][PubMed]
  • 28. Liu CH, Lin JW, Tsai FC, Yang PM, Lai MY, Chen JH, et al. Noninvasive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases. Liver Int. 2006; 26(9): 1087-94[DOI][PubMed]
  • 29. Ichino N, Osakabe K, Nishikawa T, Sugiyama H, Kato M, Kitahara S, et al. A new index for non-invasive assessment of liver fibrosis. World J Gastroenterol. 2010; 16(38): 4809-16[PubMed]
  • 30. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol. 2001; 96(11): 3142-6[DOI][PubMed]
  • 31. Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology. 2005; 41(6): 1376-82[DOI][PubMed]
  • 32. Ichida F, Tsuji T, Omata M, Ichida T, Inoue K, Kamimura T, et al. New Inuyama classification; new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun. 1996; 6(2): 112-9[DOI]
  • 33. de Torres M, Poynard T. Risk factors for liver fibrosis progression in patients with chronic hepatitis C. Ann Hepatol. 2003; 2(1): 5-11[PubMed]
  • 34. Pradat P, Voirin N, Tillmann HL, Chevallier M, Trepo C. Progression to cirrhosis in hepatitis C patients: an age-dependent process. Liver Int. 2007; 27(3): 335-9[DOI][PubMed]
  • 35. Peck-Radosavljevic M. Hypersplenism. Eur J Gastroenterol Hepatol. 2001; 13(4): 317-23[PubMed]
  • 36. Dai CY, Ho CK, Huang JF, Hsieh MY, Hou NJ, Lin ZY, et al. Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan. J Hepatol. 2010; 52(2): 160-6[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments